Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, July 2000, p. 1838-1841, Vol. 44, No. 7
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Comparative In Vitro Activities of Linezolid,
Quinupristin-Dalfopristin, Moxifloxacin, and Trovafloxacin against
Erythromycin-Susceptible and -Resistant Streptococci
Carmen
Betriu,*
Montserrat
Redondo,
M. Luisa
Palau,
Ana
Sánchez,
María
Gómez,
Esther
Culebras,
Ana
Boloix, and
Juan J.
Picazo
Servicio de Microbiología
Clínica, Hospital Clínico San Carlos, 28040 Madrid,
Spain
Received 13 December 1999/Returned for modification 25 March
2000/Accepted 18 April 2000
The in vitro activities of the new agents linezolid,
quinupristin-dalfopristin, moxifloxacin, and trovafloxacin were
determined and compared with those of penicillin, clindamycin, and four
macrolides against 53 erythromycin-resistant Streptococcus
pneumoniae, 117 S. pyogenes (64 erythromycin-susceptible and 53 -resistant), and 101 S. agalactiae (53 erythromycin-susceptible and 48 -resistant) isolates. Differentiation of macrolide resistance phenotypes was performed by the double-disk method. The genetic basis for macrolide resistance in 52 strains was also determined. The M phenotype was found
in 84.9, 6.3, and 1.9% of S. pyogenes, S. agalactiae, and S. pneumoniae isolates, respectively.
These strains were susceptible to miocamycin and clindamycin. Strains
with the inducible phenotype accounted for 27.1% of S. agalactiae isolates and 9.4% each of S. pyogenes and
S. pneumoniae isolates. All erythromycin-resistant isolates
were also resistant to the 14- and 15-membered macrolides tested.
Strains with all three phenotypes were susceptible to
2 µg of
linezolid per ml. Quinupristin-dalfopristin exhibited good in vitro
activity against all strains, irrespective of their resistance to
erythromycin (MICs at which 90% of the isolates tested were inhibited
[MIC90s], 0.2 to 1 µg/ml). Against the
erythromycin-resistant S. pyogenes and S. agalactiae strains, moxifloxacin and trovafloxacin were the most
active agents (MIC90s, 0.1 µg/ml). The new antimicrobials evaluated may be alternative agents to treat infections caused by
macrolide-resistant as well as macrolide-susceptible streptococci.
*
Corresponding author. Mailing address: Servicio de
Microbiología Clínica, Hospital Clínico San
Carlos, Plaza Cristo Rey s/n, 28040 Madrid, Spain. Phone: 34 913303478. Fax: 34 913303478. E-mail: cbetriu{at}efd.net.
Antimicrobial Agents and Chemotherapy, July 2000, p. 1838-1841, Vol. 44, No. 7
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Varaldo, P. E., Montanari, M. P., Giovanetti, E.
(2009). Genetic Elements Responsible for Erythromycin Resistance in Streptococci. Antimicrob. Agents Chemother.
53: 343-353
[Full Text]
-
Camilli, R., Del Grosso, M., Iannelli, F., Pantosti, A.
(2008). New Genetic Element Carrying the Erythromycin Resistance Determinant erm(TR) in Streptococcus pneumoniae. Antimicrob. Agents Chemother.
52: 619-625
[Abstract]
[Full Text]
-
Tiemei, Z., Xiangqun, F., Youning, L.
(2004). Resistance Phenotypes and Genotypes of Erythromycin-Resistant Streptococcus pneumoniae Isolates in Beijing and Shenyang, China. Antimicrob. Agents Chemother.
48: 4040-4041
[Abstract]
[Full Text]
-
Montanari, M. P., Cochetti, I., Mingoia, M., Varaldo, P. E.
(2003). Phenotypic and Molecular Characterization of Tetracycline- and Erythromycin-Resistant Strains of Streptococcus pneumoniae. Antimicrob. Agents Chemother.
47: 2236-2241
[Abstract]
[Full Text]
-
Montanari, M. P., Mingoia, M., Cochetti, I., Varaldo, P. E.
(2003). Phenotypes and Genotypes of Erythromycin-Resistant Pneumococci in Italy. J. Clin. Microbiol.
41: 428-431
[Abstract]
[Full Text]
-
Leclercq, R., Courvalin, P.
(2002). Resistance to Macrolides and Related Antibiotics in Streptococcus pneumoniae. Antimicrob. Agents Chemother.
46: 2727-2734
[Full Text]
-
Odenholt, I., Lowdin, E., Gustafsson, I., Cars, O.
(2002). Pharmacodynamics of Moxifloxacin against Streptococcus pyogenes in an In Vitro Kinetic Model. Antimicrob. Agents Chemother.
46: 2046-2048
[Abstract]
[Full Text]
-
Conte, J. E. Jr., Golden, J. A., Kipps, J., Zurlinden, E.
(2002). Intrapulmonary Pharmacokinetics of Linezolid. Antimicrob. Agents Chemother.
46: 1475-1480
[Abstract]
[Full Text]
-
De Mouy, D., Cavallo, J.-D., Leclercq, R., Fabre, R., The Aforcopi-Bio Network,
(2001). Antibiotic Susceptibility and Mechanisms of Erythromycin Resistance in Clinical Isolates of Streptococcus agalactiae: French Multicenter Study. Antimicrob. Agents Chemother.
45: 2400-2402
[Abstract]
[Full Text]
-
Montanari, M. P., Mingoia, M., Giovanetti, E., Varaldo, P. E.
(2001). Differentiation of Resistance Phenotypes among Erythromycin-Resistant Pneumococci. J. Clin. Microbiol.
39: 1311-1315
[Abstract]
[Full Text]
-
Fitoussi, F., Doit, C., Geslin, P., Brahimi, N., Bingen, E.
(2001). Mechanisms of Macrolide Resistance in Clinical Pneumococcal Isolates in France. Antimicrob. Agents Chemother.
45: 636-638
[Abstract]
[Full Text]
-
Syrogiannopoulos, G. A., Grivea, I. N., Tait-Kamradt, A., Katopodis, G. D., Beratis, N. G., Sutcliffe, J., Appelbaum, P. C., Davies, T. A.
(2001). Identification of an erm(A) Erythromycin Resistance Methylase Gene in Streptococcus pneumoniae Isolated in Greece. Antimicrob. Agents Chemother.
45: 342-344
[Abstract]
[Full Text]